Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FWBI - First Wave BioPharma Inc

Close
5.29
-0.280   -5.293%

Share volume: 214,335
Last Updated: Mon 08 Jan 2024 10:00:00 PM CET
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%
$5.57
-0.28
-5.03%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
57%
Profitability 68%
Dept financing 0%
Liquidity 0%
Performance 75%
Performance
5 Days
32.62%
1 Month
-12.70%
3 Months
-15.61%
6 Months
-80.25%
1 Year
-96.21%
2 Year
-99.91%
Key data
Stock price
$5.29
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.75 - $149.80
52 WEEK CHANGE
-$0.96
MARKET CAP 
71.415 M
YIELD 
N/A
SHARES OUTSTANDING 
13.500 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
-0.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,677,243
AVERAGE 30 VOLUME 
$2,272,475
Company detail
CEO: James Sapirstein
Region: US
Website: https://www.azurrx.com/
Employees: 12
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Recent news